Xeloda 150mg & 500mg Tablet
PDF Leaflet Revision Date: 30 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of breast, colorectal, and gastric cancers.
Dosage (summary)
1,250 mg/mu00b2 twice daily for 14 days, followed by 7 days rest.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; breastfeeding not recommended during treatment.
Key Drug Interactions
- Warfarin
- Phenytoin
- Sorivudine
Contraindications
- Hypersensitivity to capecitabine
- Severe renal impairment
- Severe hepatic impairment
- Dihydropyrimidine dehydrogenase deficiency
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Hand-foot syndrome
Counselling Points
- Take with water within 30 mins after meals.
- Report any severe side effects immediately.
- Use effective contraception during treatment.
Serious warnings
- Risk of severe toxicity
- Monitor INR with warfarin
- Dehydration risk
Important Disclaimer
The Xeloda 150mg & 500mg Tablet professional information leaflet below is the property of Roche and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
